Metastatic Triple-negative Breast Cancer Drug Trodelvy Available at Biologics by McKesson
Sacituzumab govitecan-hziy, approved by the FDA on April 22, 2020, is the first in its class to treat metastatic, triple-negative breast cancer in patients who have received at least 2 prior therapies for metastatic disease.
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Immunomedics, Inc. as a specialty pharmacy provider for Trodelvy (sacituzumab govitecan-hziy) for the treatment of triple-negative breast cancer (TNBC).
Trodelvy, approved by the FDA on April 22, 2020, is the first in its class to treat metastatic, triple-negative breast cancer (mTNBC) in patients who have received at least two prior therapies for metastatic disease. This intravenous infusion, third-line drug was granted both Breakthrough Therapy and Fast Track designation for patients with TNBC.
“This significant new therapy fills a gap in the TNBC space, giving patients with late-stage cancer another chance,” said Brandon Tom, vice president of Commercial Services for Biologics. “It’s an honor for us to be chosen by Immunomedics as the sole distributor for this drug, and we believe that our collaboration with them will benefit patients as well. For those patients who have been on two drugs prior to receiving Trodelvy, they can continue to get care from the clinical team they’ve come to know and trust.”
Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800-850-4306), fax (800-823-4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
About Biologics by McKesson
Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.
SOURCE: Biologics by McKesson